Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies; Availabilty
Document ID: FDA-2011-D-0872-0001
Comments
Total: 18
-
MedImmune, LLC - Comment
Posted : 02/28/2012 ID ：FDA-2011-D-0872-0003 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Erio Barale-Thomas - Comment
Posted : 02/28/2012 ID ：FDA-2011-D-0872-0004 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Erio Barale-Thomas - Comment
Posted : 02/28/2012 ID ：FDA-2011-D-0872-0005 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Statisticians in the Pharmaceutical Industry (PSI) - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0006 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
AstraZeneca - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0007 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Society of Toxicologic Pathology (STP) - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0008 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Society of Toxicologic Pathology (STP) - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0009 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Amgen, Inc. - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0010 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Bristol-Myers Squibb - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0011 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
PhRMA - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0012 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Merck & Co., Inc. - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0013 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Biogen Idec - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0014 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Abbott - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0015 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Gilead Sciences, Inc. - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0016 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Critical Path Institute - Comment
Posted : 04/12/2012 ID ：FDA-2011-D-0872-0017 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Genentech - Comment
Posted : 04/25/2012 ID ：FDA-2011-D-0872-0018 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
Pfizer, Inc. - Comment
Posted : 04/25/2012 ID ：FDA-2011-D-0872-0019 Agency : FDA -
Mar 29,2012 11:59 PM ET
-
GlaxoSmithKline - Comment
Posted : 08/16/2012 ID ：FDA-2011-D-0872-0020 Agency : FDA -
Mar 29,2012 11:59 PM ET